![CLL Society](/img/default-banner.jpg)
- Видео 313
- Просмотров 87 759
CLL Society
Добавлен 25 мар 2017
CLL Society is an inclusive, patient-centric, physician-curated 501c3 nonprofit organization whose mission is to address the unmet needs of the chronic lymphocytic leukemia and small lymphocytic lymphoma (CLL/SLL) community through patient education, advocacy, support, and research.
In 2005, when Dr. Brian Koffman was diagnosed with CLL, he and his wife, Patty, sought to define and acquire the best possible care for one CLL patient: Brian. Uncovering critical, unmet needs within the CLL community, they created the nonprofit CLL Society in 2013 to function as a conduit, making vital support and credible, cutting-edge treatment information available to all CLL patients and their caregivers. Today, CLL Society serves tens of thousands of CLL patients and their families and caregivers, as well as the CLL medical community around the world.
Please visit our website at cllsociety.org/.
In 2005, when Dr. Brian Koffman was diagnosed with CLL, he and his wife, Patty, sought to define and acquire the best possible care for one CLL patient: Brian. Uncovering critical, unmet needs within the CLL community, they created the nonprofit CLL Society in 2013 to function as a conduit, making vital support and credible, cutting-edge treatment information available to all CLL patients and their caregivers. Today, CLL Society serves tens of thousands of CLL patients and their families and caregivers, as well as the CLL medical community around the world.
Please visit our website at cllsociety.org/.
Immunity and CLL: It’s Complicated but Understandable
Join CLL Society for an informative and comprehensive webinar covering the immune system and chronic lymphocytic leukemia (CLL). Drs. Soumerai and Chang will explain the complexities of CLL, its impact on the immune system, and strategies for managing associated risks including secondary cancers and common infections. They will discuss important prevention steps, screenings, and what we know about reconstituting the immune system.
Access resources from the webinar and learn more by visiting CLL Society at: cllsociety.org/2024/07/immunity-and-cll-its-complicated-but-understandable/
__________________________________________________________________________________________
CLL Society Website: ...
Access resources from the webinar and learn more by visiting CLL Society at: cllsociety.org/2024/07/immunity-and-cll-its-complicated-but-understandable/
__________________________________________________________________________________________
CLL Society Website: ...
Просмотров: 669
Видео
Chronic Lymphocytic Leukemia (CLL) in Adolescents and Young Adults - ASH 2023
Просмотров 113День назад
Chronic lymphocytic leukemia (CLL) is a disease usually seen in older adults (the median age of diagnosis is 69), but it can also occur in adolescents and young adults (15 to 39 years of age). Because it is rare in younger patients, little information is available on their characteristics and outcomes. This study aimed to characterize the clinical characteristics, prognostic factors, and surviv...
First-line Treatment Outcomes in Patients with SLL (Small Lymphocytic Lymphoma) - ASH 2023
Просмотров 265День назад
In current classification systems, chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are considered the same disease characterized by malignant B cells. However, they are slightly different based on the primary location of the disease in the body. In CLL, most malignant cells are found in the peripheral blood and bone marrow, but in SLL, most malignant cells are found in t...
First-Line Venetoclax Combination Therapies for CLL - Dr. Barbara Eichhorst ASH 2023
Просмотров 31628 дней назад
In the past decade, we have seen the introduction of very effective targeted therapies for treating chronic lymphocytic leukemia (CLL) / small lymphocytic lymphoma (SLL). The GAIA (CLL13) trial is a phase 3 clinical trial of frontline time-limited venetoclax-based combination treatments vs. chemoimmunotherapy. Venetoclax-obinutuzumab and ibrutinib-venetoclax-obinutuzumab produce more prolonged ...
Tislelizumab Plus Zanubrutinib for Richter’s Transformation - Dr. Barbara Eichhorst ASH 2023
Просмотров 10828 дней назад
The combination of tislelizumab plus zanubrutinib is effective and well-tolerated for patients with Richter’s transformation. After one year, three out of four patients were still alive, and nearly one in two were still in remission. Dr. Barbara Eichhorst from the University of Cologne and colleagues presented the results at the American Society for Hematology (ASH) Annual Meeting 2023. Read th...
Triple Combination Therapy for Richter’s Transformation - Dr. Tamar Tadmor ASH 2023
Просмотров 8628 дней назад
For patients with Richter’s transformation, the combination of ibrutinib, venetoclax, and obinutuzumab may be most useful as a bridge to other therapies. While the triple combination therapy initially produced high response rates, these responses were not durable. Dr. Tamar Tadmor from Bnai-Zion Medical Center and colleagues presented the results at the American Society for Hematology (ASH) Ann...
My CAR-T Story: Peter Cozzens
Просмотров 20528 дней назад
Hearing first-hand stories from fellow patients living with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) can be invaluable when preparing to make important treatment decisions. If you are considering CAR-T as a treatment option for CLL / SLL, we invite you to watch this video series titled “My CAR-T Story,” where you will listen to testimonials from patients who have r...
My CAR-T Story: Bob Levis
Просмотров 15428 дней назад
Hearing first-hand stories from fellow patients living with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) can be invaluable when preparing to make important treatment decisions. If you are considering CAR-T as a treatment option for CLL / SLL, we invite you to watch this video series titled “My CAR-T Story,” where you will listen to testimonials from patients who have r...
My CAR-T Story: Dr. Brian Koffman
Просмотров 21528 дней назад
Hearing first-hand stories from fellow patients living with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) can be invaluable when preparing to make important treatment decisions. If you are considering CAR-T as a treatment option for CLL / SLL, we invite you to watch this video series titled “My CAR-T Story,” where you will listen to testimonials from patients who have r...
Fixed Duration vs. Continuous Duration Therapy in CLL
Просмотров 648Месяц назад
Whether or not a therapy is administered for a “fixed” or “continuous” duration is an important factor to consider when making a treatment decision with your health care team. What do these terms mean? What is the difference, and what are the pros and cons of each? Dr. Brian Koffman interviews Dr. Brian Hill to answer these questions and more. Watch the video, then take a brief quiz to test you...
Healthcare Professional Knowledge of CLL Treatments - Dr. Jeff Sharman ASH 2023
Просмотров 164Месяц назад
CLL is a complicated and rapidly changing field. Healthcare professionals need help keeping up-to-date with current treatment recommendations and new therapies for CLL. Continuing medical education activities can help improve knowledge, competence, and confidence in caring for patients with CLL. Dr. Jeff Sharman from Willamette Valley Cancer Institute and Research Center and colleagues presente...
Long-term Outcomes After Lenalidomide plus Rituximab for CLL - Dr. Benjamin Heyman ASH 2023
Просмотров 97Месяц назад
Ten-year follow-up data showed that lenalidomide plus rituximab produced high response rates in patients with chronic lymphocytic leukemia (CLL) with no significant safety signals. Lenalidomide might be useful as a combination therapy because its immunomodulatory properties can potentially improve T cell function and the immune response. Dr. Benjamin Heyman from Moores Cancer Center at the Univ...
CLL Society Facebook Live "Ask Me Anything" with Dr. Richard Furman and Jeff Folloder
Просмотров 556Месяц назад
Dr. Richard Furman joins us for CLL Society’s Facebook Live Event “Ask Me Anything”. With no prepared presentation, this event is truly dedicated to answering your questions. Dr. Furman is the Director of the CLL Research Center Division of Hematology/Oncology at Weill Cornell Medical College and a member of CLL Society’s Expert Medical Counsel. Fellow CLL/SLL patient and advocate Jeff Folloder...
CLL Society 2024 Integrative Medicine Award - Dr. Christopher Jensen
Просмотров 84Месяц назад
Christopher Jensen, MD, MSCR from University of North Carolina-Chapel Hill was awarded CLL Society’s 2024 Integrative Medicine Award for his research project titled “Combating Cancer-Related Fatigue: A Personalized Supportive Care Program.” Patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) often struggle significantly with cancer-related fatigue. The goal of ...
CLL Society 2024 Clinical Scholar Award - Dr. Jennifer Brown
Просмотров 89Месяц назад
Jennifer Brown, MD, PhD from Dana-Farber Cancer Institute was awarded CLL Society’s 2024 Clinical Scholar Award for her research project titled “Venetoclax and Obinutuzumab in Combination with Roginolisib in CLL / SLL Patients After Bruton Tyrosine Kinase (BTK) Inhibitor Failure.” For those with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) who have been previously tre...
CLL Society 2024 Young Investigator Award - Dr. Prajish Iyer
Просмотров 282Месяц назад
CLL Society 2024 Young Investigator Award - Dr. Prajish Iyer
Time Off Treatment - Chronic Lymphocytic Leukemia (CLL)
Просмотров 552Месяц назад
Time Off Treatment - Chronic Lymphocytic Leukemia (CLL)
Comparison of Venetoclax-Based Treatments for CLL - Dr. Benjamin Heyman ASH 2023
Просмотров 269Месяц назад
Comparison of Venetoclax-Based Treatments for CLL - Dr. Benjamin Heyman ASH 2023
Preclinical Study of a Dual Binding BTK Inhibitor for CLL - Dr. Adam Kittai ASH 2023
Просмотров 256Месяц назад
Preclinical Study of a Dual Binding BTK Inhibitor for CLL - Dr. Adam Kittai ASH 2023
Patient Preferences for Fixed vs. Continuous Therapies in CLL - Dr .Brian Koffman ASH 2023
Просмотров 203Месяц назад
Patient Preferences for Fixed vs. Continuous Therapies in CLL - Dr .Brian Koffman ASH 2023
Response to CLL Therapies After Fixed-Duration Venetoclax - ASH 2023 Dr. John Seymour
Просмотров 3222 месяца назад
Response to CLL Therapies After Fixed-Duration Venetoclax - ASH 2023 Dr. John Seymour
Safety of Dual Covalent and Noncovalent BTK Inhibitor for CLL - ASH 2023 Dr. Jennifer Woyach
Просмотров 1482 месяца назад
Safety of Dual Covalent and Noncovalent BTK Inhibitor for CLL - ASH 2023 Dr. Jennifer Woyach
Impact of Ibrutinib Treatment on T-Cell Exhaustion in CLL - ASH 2023 Dr. Jennifer Woyach
Просмотров 2512 месяца назад
Impact of Ibrutinib Treatment on T-Cell Exhaustion in CLL - ASH 2023 Dr. Jennifer Woyach
Pirtobrutinib and Prior BCL2 Inhibitor Exposure in CLL - ASH 2023 Dr. Jennifer Woyach
Просмотров 1452 месяца назад
Pirtobrutinib and Prior BCL2 Inhibitor Exposure in CLL - ASH 2023 Dr. Jennifer Woyach
A New Treatment Combination Being Studied for High-Risk CLL - Dr. Boyu Hu ASH 2023
Просмотров 3192 месяца назад
A New Treatment Combination Being Studied for High-Risk CLL - Dr. Boyu Hu ASH 2023
Immunoglobulin Replacement Therapy for Patients with CLL - Dr. Jacob Soumerai ASH 2023
Просмотров 3752 месяца назад
Immunoglobulin Replacement Therapy for Patients with CLL - Dr. Jacob Soumerai ASH 2023
The Role of BCL2 Inhibitors in Clonal Hematopoiesis - Dr. Piers Blombery ASH 2023
Просмотров 992 месяца назад
The Role of BCL2 Inhibitors in Clonal Hematopoiesis - Dr. Piers Blombery ASH 2023
Initial Study and Findings for BTK Degrader to Treat CLL - Dr. Alexey Danilov ASH 2023
Просмотров 2982 месяца назад
Initial Study and Findings for BTK Degrader to Treat CLL - Dr. Alexey Danilov ASH 2023
Incidence of Richter’s Transformation in the Targeted Therapy Era - Dr. Paul Hampel ASH 2023
Просмотров 3812 месяца назад
Incidence of Richter’s Transformation in the Targeted Therapy Era - Dr. Paul Hampel ASH 2023
Patient Well-Being After a CLL Diagnosis - ASH 2023
Просмотров 2262 месяца назад
Patient Well-Being After a CLL Diagnosis - ASH 2023